Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment
Aafke Meerveld-Eggink, Niels M. Graafland, Sofie Wilgenhof, Johannes V. van Thienen, Ferry Lalezari, Michael Grant, Bernadett Emma Szabados, Yasmin Abu‐Ghanem, Teele Kuusk, Ekaterini Boleti, Christian U. Blank, John B.A.G. Haanen, Thomas B. Powles, Axel Bex
Journal
- ISSN / E-ISSN
- — / —
- DOI
- 10.1016/j.euros.2021.11.003 ↗
- Volume · Issue · Pages
- 35 · — · 54-58
- Publisher
- Elsevier BV
- Article URL
- https://doi.org/10.1016/j.euros.2021.11.003 ↗
- Article details
- Unverified
Publication date (each date has its type and source)
01 Jan 2022
OpenAlex publication date · source: OpenAlex
| Type | Date | Source |
|---|---|---|
| OpenAlex publication date | 01 Jan 2022 | OpenAlex |
Keywords (as given): metastatic renal cell carcinoma; nivolumab; ipilimumab; immune checkpoint inhibitors; first-line immunotherapy; overall survival; immune-related adverse events; IMDC risk stratification; partial response; complete response
HEC Status at Publication Not the journal's current status
HEC Status at PublicationConclusive
HEC status at publication
Recognized
Y
Based on the recorded HEC dataset applicable to the article's publication date. Listed as Y in the HEC list for hjrs 2021-22 V2.
- Journal
- European Urology Open Science
- Publication date used
- 01 Jan 2022 (OpenAlex publication date)
- Applicable HEC period
- hjrs 2021-22 V2 (version 1) · 01 Jul 2021 – 30 Jun 2022
- Category
- Y
- Recognition status
- Recognized (OK_RECORD_FOUND)
- Source
- hjrs-2021-22 row 19776
- Verification status
- Verified against source · last verified 16 Oct 2026
This is an automatically generated summary based on the information available on the publication date. Terms & conditions apply.